Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sigwart, U.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sigwart, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Non-surgical myocardial reduction for patients with hypertrophic obstructive cardiomyopathy

U. Sigwart1

Royal Brompton Hospital, London, U.K.

1 Correspondence: Ulrich Sigwart, MD, FACC, FESC, FRCP, Department of Invasive Cardiology, Royal Brompton Hospital, Sydney Street, London SW3 6NP, U.K.

Abstract

Until 1994 surgical myotomy-myectomy was the most effective symptomatic treatment for patients with symptoms of hypertrophic cardiomyopathy and dynamic left ventricular outflow tract obstruction refractory to pacing and drug treatment. Similar functional results can now be achieved by the creation of an alcohol-induced septal infarction using a catheter technique. This therapeutic myocardial necrosis results in widening of the left ventricular outflow tract with consequent gradient reduction, followed by clinical and objective improvement, as well as further gradient reduction as a result of left ventricular remodelling.

Key Words: catheter intervention • hypertrophic obstructive cardiomyopathy • percutaneous myocardial ablation • ventricular remodelling

References

  1. McKenna WJ, Coccolo F, Elliot PM. Genes and disease expression in hypertrophic cardiomyopathy. Lancet. 1998;352:1162–1163[CrossRef][Web of Science][Medline]
  2. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248–1257[Abstract/Free Full Text]
  3. Wigle ED, Rakowski H, Kimball BP, et al. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation. 1995;92:1680–1692[Free Full Text]
  4. Klues HG, Maron BJ, Dollar AL, et al. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation. 1992;85:1651–1660[Abstract/Free Full Text]
  5. Liberthson RR. Sudden death from cardiac causes in children and young adults. N Engl J Med. 1996;334:1039–1044[Free Full Text]
  6. Kuhn H, Gietzen F, Leuner C, et al. Induction of subaortic ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Eur Heart J. 1997;18:846–851[Abstract/Free Full Text]
  7. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775–785[Free Full Text]
  8. Maron BJ. Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: too soon for a rush to judgement? J Am Coll Cardiol. 1996;27:431–432[CrossRef][Web of Science][Medline]
  9. Schulte HD, Gramsch-Zabel H, Schwartzkopff B. Hypertrophic obstructive cardiomyopathy: surgical treatment [in German]. Schweiz Med Wochenschr. 1995;125:1940–1949[Web of Science][Medline]
  10. Robbins RC, Stinson EB, Daily PO. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 1996;111:586–594[Abstract/Free Full Text]
  11. Heric B, Lytle BW, Miller DP, et al. Surgical management of hypertrophic obstructive cardiomyopathy: early and late results. J Thorac Cardiovasc Surg. 1995;110:195–208[Abstract/Free Full Text]
  12. Schoendube FA, Klues HG, Reith S, et al. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mural apparatus. Circulation. 1995;92(suppl II):122–127[Abstract/Free Full Text]
  13. Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic obstructive cardiomyopathy with severe obstruction due to anomalous papillary muscle. Circulation. 1998;98:2505–2508[Abstract/Free Full Text]
  14. Sigwart U. Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211–214[CrossRef][Web of Science][Medline]
  15. Seggewiss H, Gleichmann U, Faber L, et al. Percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy: acute results and 3-month followup in 25 patients. J Am Coll Cardiol. 1998;31:252–258[Abstract/Free Full Text]
  16. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute and 3-months follow-up results with respect to myocardial contrast echocardiography. Circulation. 1998;98:2415–2421[Abstract/Free Full Text]
  17. Faber L, Seggewiss H, Fassbender D, et al. Guiding of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy by myocardial contrast echocardiography. J Interv Cardiol. 1998;11:443–448[CrossRef][Web of Science]
  18. Faber L, Seggewiss H, Ziemssen P, Gleichmann U. Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myo cardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Catheter Cardiovasc Interv. 1999;47:462–466[CrossRef][Web of Science][Medline]
  19. Ruzyllo W, Chojnowska L, Demkow M, et al. Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J. 2000;21:770–777[Abstract/Free Full Text]
  20. Maron BJ, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999;281:650–655[Abstract/Free Full Text]
  21. Seggewiss H, Faber L, Meyners W, et al. Simultaneous percutaneous treatment in hypertrophic obstructive cardiomyopathy and coronary artery disease: a case report. Cathet Cardiovasc Diagn. 1998;44:65–69[CrossRef][Web of Science][Medline]
  22. Gleichmann U, Seggewiss H, Faber L, et al. Catheter treatment of hypertrophic obstructive cardiomyopathy [in German]. Dtsch Med Wochenschr. 1996;21:679–685
  23. Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hyper trophic obstructive cardiomyopathy. Eur Heart J. 1999;20:1342–1354[Abstract/Free Full Text]
  24. Seggewiss H, Faber L, Strick S, et al. Ongoing clinical and noninvasive improvement after percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy (HOCM). [abstract]Circulation. 1998;98(suppl I):506
  25. Knight C, Kurbaan AS, Seggewiss H, et al. Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation. 1997;95:2075–2081[Abstract/Free Full Text]
  26. Lakkis N, Kleiman N, Killip D, et al. Hypertrophic obstructive cardiomyopathy: alternative therapeutic options. Clin Cardiol. 1997;20:417–418[Web of Science][Medline]
  27. Bhargava B, Agarval R, Kaul U, et al. Transcatheter alcohol ablation of the septum in a patient of hypertrophic obstructive cradiomyopathy. Cathet Cardiovasc Diagn. 1997;41:56–58[CrossRef][Web of Science][Medline]
  28. Kornacewicz-Jach Z, Gil R, Wojtarowicz A, et al. Early results of alcohol ablation of the septal branch of coronary artery in patients with hypertrophic obstructive cardiomyopathy [in Polish]. Kardiol Pol. 1998;48:105–112
  29. Nagueh SF, Lakkis NM, He Z-X, et al. Role of myocardial contrast echocardiography during nonsurgical reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1998;32:225–229[Abstract/Free Full Text]
  30. Seggewiss H, Faber L, Ziemssen P, et al. Age related acute results in percutaneous septal ablation in hypertrophic obstructive cardiomyopathy [abstract]. J Am Coll Cardiol. 2000;35(suppl A):188A[CrossRef]
  31. Seggewiss H, Faber L, Ziemssen P, Meyners W. Non-surgical septal ablation (PTSMA) in patients with NYHA class IV and hypertrophic obstructive cardiomyopathy (HOCM) [abstract]. Circulation. 1999;100(suppl I):515
  32. Kuhn H, Gietzen F, Leuner CH, et al. Transcoronary ablation of septal hypertrophy: a new treatment for hypertrophic obstructive cardiomyopathy. Z Kardiol. 2000;89(suppl 4):41–54
  33. Seggewiss H, Faber L, Percutaneous septal ablation for hypertrophic cardiomyopathy and mid-ventricular obstruction. Eur J Echocardiography (in press).
  34. Kurbaan AS, Seggewiss H, Henein MY, et al. Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: long-term follow-up of the early patients [abstract]. Circulation. 1997;96:463 (suppl)
  35. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg. 1999;47:94–100[Web of Science][Medline]
  36. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart. 2000;83:326–331[Abstract/Free Full Text]
  37. Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001;103:1492–1496[Abstract/Free Full Text]
  38. Ziemssen P, Faber L, Schlichting J, et al. Percutaneous septal ablation in patients with hypertrophic obstructive cardiomyopathy results in improvement of exercise capacity [abstract]. J Am Coll Cardiol. 2000;35:182A
  39. Curtius JM, Stoecker J, Loesse B, et al. Changes of the degree of hypertrophy in hypertrophic obstructive cardiomyopathy under medical and surgical treatment. Cardiology. 1989;76:255–263[Web of Science][Medline]
  40. Seggewiss H. Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy. Curr Cardiol Rep. 2001;3:160–166[Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sigwart, U.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sigwart, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?